Danaher

The company has shut down the Veris molecular diagnostics product line, which Beckman Coulter spent years developing, as a result of its acquisition of Cepheid.

The firm's European subsidiary is offering the new senior notes to repay, in part, all outstanding aggregate principal amounts on senior notes due later this month.

The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio. 

Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.

The company beat Wall Street analysts' expectations for sales and earnings per share during the quarter.

A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.

Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.